Biotechnology company conducting clinical operations in researching, developing and delivering psychedelics medicines Awakn Life Sciences Corp has announced that it will begin trading on NEO Exchange Inc. from June 23.
Awakn Life Sciences will make its debut in the market under the ticker symbol ‘AWKN’
The company’s chief executive officer, Anthony Tennyson, said this listing will enable the company to accelerate the execution of its drug discovery, therapy development, advanced analytics and open clinic roll out programs.
“Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” added the CEO.
